Emerging drugs for ocular hypertension (Q37847182)

24 August 2017

1 reference

title

Emerging drugs for ocular hypertension (English)

1 reference

24 August 2017

main subject

arterial hypertension

0 references

author name string

Anne J Lee

series ordinal

1

1 reference

24 August 2017

Ivan Goldberg

series ordinal

2

1 reference

24 August 2017

language of work or name

English

0 references

publication date

1 March 2011

1 reference

Expert Opinion on Emerging Drugs

24 August 2017

published in

1 reference

24 August 2017

volume

16

1 reference

24 August 2017

issue

1

1 reference

24 August 2017

page(s)

137-161

1 reference

Blood pressure, perfusion pressure, and glaucoma.

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Pathogenesis of ganglion "cell death" in glaucoma and neuroprotection: focus on ganglion cell axonal mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

The number of people with glaucoma worldwide in 2010 and 2020

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Number of people with glaucoma worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

The Barbados Eye Study. Prevalence of open angle glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Prevalence of open-angle glaucoma in Australia. The Blue Mountains Eye Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Validated prediction model for the development of primary open-angle glaucoma in individuals with ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Racial differences in the cause-specific prevalence of blindness in east Baltimore

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Prevalence of open-angle glaucoma and ocular hypertension in Latinos: the Los Angeles Latino Eye Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Biostatistical analysis of the collaborative glaucoma study. I. Summary report of the risk factors for glaucomatous visual-field defects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Risk factors for the development of glaucomatous visual field loss in ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Delayed functional loss in glaucoma. LII Edward Jackson Memorial Lecture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Targeting outflow facility in glaucoma management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Rho GTPase/Rho kinase inhibition as a novel target for the treatment of glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Changes in aqueous humor dynamics with age and glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

'What controls aqueous humour outflow resistance?'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

The regulation of trabecular meshwork and ciliary muscle contractility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Morphological changes in glaucomatous eyes and the role of TGFbeta2 for the pathogenesis of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Glaucoma: a review of adjunctive therapy and new management strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Is addition of a third or fourth antiglaucoma medication effective?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Cost-effectiveness of treating ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Management of ocular hypertension: a cost-effectiveness approach from the Ocular Hypertension Treatment Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Glaucoma and disability: which tasks are affected, and at what stage of disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Evaluation of quality of life for patients with glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Visual function tests, eye disease and symptoms of visual disability: a population-based assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Glaucoma and quality of life: the Salisbury Eye Evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Impact of visual field loss on health-related quality of life in glaucoma: the Los Angeles Latino Eye Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Correlation of visual field with quality-of-life measures at diagnosis in the Collaborative Initial Glaucoma Treatment Study (CIGTS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

A clinician's guide to the assessment and management of nonadherence in glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

First-year treatment costs among new initiators of topical prostaglandin analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Pharmacotherapy of intraocular pressure: part I. Parasympathomimetic, sympathomimetic and sympatholytics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Commercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Glaucoma treatment in Australia: changing patterns of therapy 1994-2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Update on the mechanism of action of bimatoprost: a review and discussion of new evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Clinical pharmacology of bimatoprost

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

An update on bimatoprost in glaucoma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

The prostanoid EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Increased matrix metalloproteinases 1, 2, and 3 in the monkey uveoscleral outflow pathway after topical prostaglandin F(2 alpha)-isopropyl ester treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Prostaglandins increase trabecular meshwork outflow facility in cultured human anterior segments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Pharmacotherapy of intraocular pressure - part II. Carbonic anhydrase inhibitors, prostaglandin analogues and prostamides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Effects of prostaglandins on the aqueous humor outflow pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Update on prostaglandin analogs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

24-hour intraocular pressure control obtained with evening- versus morning-dosed travoprost in primary open-angle glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Identification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Latanoprost and cystoid macular edema: is there a causal relation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Latanoprost and herpes simplex keratitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Reactivation of herpes simplex virus keratitis after initiating bimatoprost treatment for glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Iris cyst secondary to latanoprost mimicking iris melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Iris cyst associated with topical administration of latanoprost.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Drug points. Exacerbation of angina associated with latanoprost

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

The mechanism of timolol in lowering intraocular pressure. In the normal eye.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Comparison of aqueous and gellan ophthalmic timolol with placebo on the 24-hour heart rate response in patients on treatment for glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Comparison of once-daily nonpreserved timolol and timolol maleate gel-forming solution associated with latanoprost

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Ocular levobunolol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Ocular metipranolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in glaucoma and ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

A 7 year prospective comparative study of three topical beta blockers in the management of primary open angle glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Association between low plasma levels of ophthalmic timolol and haemodynamics in glaucoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Topical beta blockers in asthmatic patients-is it safe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Ocular carteolol: a review of its use in the management of glaucoma and ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Primary drug treatment for glaucoma: beta-blockers versus other medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Topical timolol decreases plasma high-density lipoprotein cholesterol level.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Effects of carteolol and timolol on plasma lipid profiles in older women with ocular hypertension or primary open-angle glaucoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Acute Pulmonary Edema Associated with Ocular Metipranolol Use

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Carbonic anhydrase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Acetazolamide-associated aplastic anaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Short-term ocular tolerability of dorzolamide 2% and brinzolamide 1% vs placebo in primary open-angle glaucoma and ocular hypertension subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Dorzolamide: development and clinical application of a topical carbonic anhydrase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Brinzolamide : a review of its use in the management of primary open-angle glaucoma and ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Additive intraocular pressure lowering effect of various medications with latanoprost

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Irreversible corneal decompensation in patients treated with topical dorzolamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Literature review and meta-analysis of topical carbonic anhydrase inhibitors and ocular blood flow

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

The vasodilating effect of acetazolamide and dorzolamide involves mechanisms other than carbonic anhydrase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Vascular risk factors for primary open angle glaucoma: the Egna-Neumarkt Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Relationship between ocular perfusion pressure and retrobulbar blood flow in patients with glaucoma with progressive damage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Blood pressure, perfusion pressure, and open-angle glaucoma: the Los Angeles Latino Eye Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Effects of dorzolamide 2% added to timolol maleate 0.5% on intraocular pressure, retrobulbar blood flow, and the progression of visual field damage in patients with primary open-angle glaucoma: a single-center, 4-year, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Predictors for visual field progression and the effects of treatment with dorzolamide 2% or brinzolamide 1% each added to timolol 0.5% in primary open-angle glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Experimental and clinical evidence for brimonidine as an optic nerve and retinal neuroprotective agent: an evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Meta-analysis of randomised controlled trials comparing latanoprost with brimonidine in the treatment of open-angle glaucoma, ocular hypertension or normal-tension glaucoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

21 January 2018

Brimonidine for glaucoma

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Surveillance of glaucoma medical therapy in a Glasgow teaching hospital: 26 years' experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Apparent central nervous system depression in infants after the use of topical brimonidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Safety and efficacy of brimonidine in children with glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Pharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Duration of IOP reduction with travoprost BAK-free solution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

The economic burden of major adult visual disorders in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Direct costs of glaucoma and severity of the disease: a multinational long term study of resource utilisation in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

A multicentre, retrospective study of resource utilization and costs associated with glaucoma management in France and Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

The rising cost of glaucoma drugs in Ireland 1996-2003

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Cost considerations in the medical management of glaucoma in the US: estimated yearly costs and cost effectiveness of bimatoprost compared with other medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Trends in glaucoma surgery before and after the introduction of new topical glaucoma pharmacotherapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Late-stage, primary open-angle glaucoma in Europe: social and health care maintenance costs and quality of life of patients from 4 countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Costs and utilization of end-stage glaucoma patients receiving visual rehabilitation care: a US multisite retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Cost of illness of glaucoma: a critical and systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

The economic implications of glaucoma: a literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Fixed-combination and emerging glaucoma therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Partial agonists, full agonists, antagonists: dilemmas of definition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Comparison of Prostaglandin F2α, Bimatoprost (Prostamide), and Butaprost (EP2 Agonist) on Cyr61 and Connective Tissue Growth Factor Gene Expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Contribution of ROCK in contraction of trabecular meshwork: proposed mechanism for regulating aqueous outflow in monkey and human eyes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Mechanistic basis of Rho GTPase-induced extracellular matrix synthesis in trabecular meshwork cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Reduction of intraocular pressure by topical administration of an inhibitor of the Rho-associated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Effects of ML-7 and Y-27632 on carbachol- and endothelin-1-induced contraction of bovine trabecular meshwork.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Involvement of RhoA and possible neuroprotective effect of fasudil, a Rho kinase inhibitor, in NMDA-induced neurotoxicity in the rat retina

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Endothelin-evoked contractions in bovine ciliary muscle and trabecular meshwork: interaction with calcium, nifedipine and nickel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Effects of endothelin-1 on calcium-independent contraction of bovine trabecular meshwork

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Endothelin-like immunoreactivity in the aqueous humour and in conditioned medium from cultured ciliary epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Endothelin-like immunoreactivity in aqueous humor of patients with primary open-angle glaucoma and cataract.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Endothelin antagonism: effects of FP receptor agonists prostaglandin F2alpha and fluprostenol on trabecular meshwork contractility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

The role of the actomyosin system in regulating trabecular fluid outflow

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Effects of novel ethacrynic acid derivatives on human trabecular meshwork cell shape, actin cytoskeletal organization, and transcellular fluid flow

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Effects of the new ethacrynic acid derivative SA9000 on intraocular pressure in cats and monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Effect of low-dose latrunculin B on anterior segment physiologic features in the monkey eye.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Electrophysiological properties of cultured human trabecular meshwork cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Regulation of trabecular meshwork contractility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Protective effects of melatonin in experimental free radical-related ocular diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

A placebo-controlled 3-year study of a calcium blocker on visual field and ocular circulation in glaucoma with low-normal pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Ocular hypotensive action of topical flunarizine in the rabbit: role of sigma 1 recognition sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Pharmacokinetic profile of topical flunarizine in rabbit eye and plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Effect of flunarizine, a calcium channel blocker, on intraocular pressure and aqueous humor dynamics in monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Effect of calcium channel blockers on intraocular pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Comparative study of topical application of timolol and verapamil in patients with glaucoma within 6 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Mitochondrial defects and dysfunction in calcium regulation in glaucomatous trabecular meshwork cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Activation of a tissue-specific stress response in the aqueous outflow pathway of the eye defines the glaucoma disease phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Presence of an established calcification marker in trabecular meshwork tissue of glaucoma donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Increased expression of iron-regulating genes in monkey and human glaucoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Mouse brains deficient in H-ferritin have normal iron concentration but a protein profile of iron deficiency and increased evidence of oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Lipid peroxidation in open-angle glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Selective serotonin reuptake inhibitors: a review of its effects on intraocular pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

AL-34662: a potent, selective, and efficacious ocular hypotensive serotonin-2 receptor agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Characterization of serotonin receptors in the iris + ciliary body of the albino rabbit

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Localization of 5-hydroxytryptamine1A and 5-hydroxytryptamine7 receptors in rabbit ocular and brain tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Melatonin in the eye: implications for glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Ocular hypotensive effects of melatonin receptor agonists in the rabbit: further evidence for an MT3 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

The presence of functional melatonin receptors in the iris-ciliary processes of the rabbit eye.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Melatonin receptor mRNA and protein expression in Xenopus laevis nonpigmented ciliary epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Involvement of melatonin MT(3) receptors in the regulation of intraocular pressure in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Effect of 5-MCA-NAT, a putative melatonin MT3 receptor agonist, on intraocular pressure in glaucomatous monkey eyes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Effects of melatonin on the nitric oxide treated retina.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Melatonin decreases neurovascular oxidative/nitrosative damage and protects against early increases in the blood-brain barrier permeability after transient focal cerebral ischemia in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Cannabinoids and glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

R(+)-methanandamide and other cannabinoids induce the expression of cyclooxygenase-2 and matrix metalloproteinases in human nonpigmented ciliary epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Pharmacology and toxicology of Cannabis derivatives and endocannabinoid agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Anterior juxtascleral delivery of anecortave acetate in eyes with primary open-angle glaucoma: a pilot investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Mechanisms linking adenosine A1 receptors and extracellular signal-regulated kinase 1/2 activation in human trabecular meshwork cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Modulation of conventional outflow facility by the adenosine A1 agonist N6-cyclohexyladenosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

A(1)-, A(2A)- and A(3)-subtype adenosine receptors modulate intraocular pressure in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Effects of adenosine agonists on intraocular pressure and aqueous humor dynamics in cynomolgus monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Modulation of aqueous humor outflow by ionic mechanisms involved in trabecular meshwork cell volume regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

The beta-adrenergic blocking agents and the treatment of glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

New treatments for ocular hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

RNA interference is mediated by 21- and 22-nucleotide RNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Characterization of pilocarpine-loaded chitosan/Carbopol nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Barriers to glaucoma drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Prolonged effect of liposomes encapsulating pilocarpine HCl in normal and glaucomatous rabbits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Nanoemulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Sustained delivery of timolol maleate from poly(lactic-co-glycolic acid)/poly(lactic acid) microspheres for over 3 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Influence of hydroxypropyl beta-cyclodextrin on the corneal permeation of pilocarpine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Cyclodextrin complexes of sulfonamide carbonic anhydrase inhibitors as long-lasting topically acting antiglaucoma agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

A medical device/drug delivery system for treatment of glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Timolol transport from microemulsions trapped in HEMA gels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Ophthalmic drug delivery through contact lenses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Effect of posterior sub-tenon administration of triamcinolone acetonide on leukocyte dynamics in rat retinal microcirculation after panretinal photocoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Neuroprotection: extrapolating from neurologic diseases to the eye.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Modulation of extracellular matrix turnover in the trabecular meshwork

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Future target molecules in antiglaucoma therapy: tgf-Beta may have a role to play

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Improved systemic safety and risk–benefit ratio of topical 0.1% timolol hydrogel compared with 0.5% timolol aqueous solution in the treatment of glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

The long-term safety and efficacy of brinzolamide 1.0% (Azopt) in patients with primary open-angle glaucoma or ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Evaluation of Serotonin Levels in Human Aqueous Humor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

Hypertension, Perfusion Pressure, and Primary Open-angle Glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.521631

10.1517/14728214.2011.521631

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference